Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3696413 | 0.86 | KCNA3 (0.61) | KCNA3TAAR1ALDH1A1RECQLLTA4H | |
| SCHEMBL497461 | 0.84 | KCNA3 (0.63) | KCNA3TAAR1ALDH1A1RECQLALOX15 | |
| SCHEMBL6539549 | 0.84 | KCNA3 (0.73) | KCNA3TAAR1ALDH1A1RECQLLTA4H | |
| SCHEMBL5583706 | 0.84 | KCNA3 (0.65) | KCNA3TAAR1ALDH1A1RECQLLTA4H | |
| SCHEMBL2150312 | 0.83 | KCNA3 (0.32) | KCNA3 | |
| Hydrochloric Acid SCHEMBL10519295 | 0.82 | KCNA3 (0.60) | KCNA3TAAR1ALDH1A1RECQLALOX15 | |
| Hydrochloric Acid SCHEMBL10555789 | 0.82 | KCNA3 (0.60) | KCNA3TAAR1ALDH1A1RECQLALOX15 | |
| Ammonia Solution, Strong SCHEMBL28919640 | 0.82 | KCNA3 (0.60) | KCNA3TAAR1ALDH1A1RECQLALOX15 | |
| SCHEMBL76993 | 0.77 | LMNA (0.61) | LTA4HMAOAPTGS1HDAC6LMNA | |
| SCHEMBL920703 | 0.77 | APP (0.59) | ALDH1A1MAOAPTGS1HDAC6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0711290-A1 | METHYLGUANIDINE DERIVATIVES, METHODS FOR PREPARING SAME AND COMPOSITIONS CONTAINING SAID DERIVATIVES | SANOFI (FR) | 1996-05-15 | — | — | EP | claimed |
| WO-1995004052-A1 | METHYLGUANIDINE DERIVATIVES, METHODS FOR PREPARING SAME AND COMPOSITIONS CONTAINING SAID DERIVATIVES | SANOFI (FR) | 1995-02-09 | — | — | WO | claimed |
| US-6743776-B2 | ANTIFUNGAL, BETA-1,3-GLUCAN SYNTHASE INHIBITOR, PNEUMOCYSTIS CARINII; AMIDATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-0941236-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998023637-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-04 | — | — | WO | disclosed |
| EP-0711290-A1 | METHYLGUANIDINE DERIVATIVES, METHODS FOR PREPARING SAME AND COMPOSITIONS CONTAINING SAID DERIVATIVES | SANOFI (FR) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995004052-A1 | METHYLGUANIDINE DERIVATIVES, METHODS FOR PREPARING SAME AND COMPOSITIONS CONTAINING SAID DERIVATIVES | SANOFI (FR) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | NGLY1, CHIT1, MANBA | KCNA3 2839/4885TAAR1 2882/4885ALDH1A1 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.